Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial…
AQST-109 is the first and only orally delivered epinephrine product candidate in clinical developmentFastest median time to maximum concentration (Tmax) in studies to date at 12 minutes Study continues to show AQST-109 is safe and well…